Traditionally, randomized trials of drug treatment in patients with hypertension, dyslipidemia, and diabetes have evaluated either the levels of the risk factors themselves or the incidence of cardiovascular events as outcomes. Nutritional-hygienic interventions such as dietary changes, weight loss, and physical activity have typically been evaluated in terms of the incidence of hypertension, hyperlipidemia, or diabetes. 1,2 An emerging genre of randomized trials has posed two related questions 1 : whether, among patients with borderline levels of a risk factor, drug treatments will prevent the onset of these thresholddefined conditions; and 2 whether reduced incidence will persist after the cessation of drug treatment, in a "carryover" effect of treatment.
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Regarding the first question, it is not clear that a public health rationale exists for conduct of drug-treatment trials designed to prevent the onset of a condition that, in the normal course of clinical care, simply signals the start of drug-treatment. In contrast the second question, testing the carryover hypothesis of delayed incidence of disease after cessation of drug therapy, is a potentially important one that requires careful study design and interpretation.
Two recent examples are DREAM 3 and TROPHY. 4 While the DREAM trial 3 reported the association between rosiglitazone treatment and the onset of diabetes, the carryover hypothesis is still under investigation.
The TROPHY trial evaluated candesartan compared with placebo on the incidence of hypertension as well as the hypothesized carryover effects after the cessation of drug treatment. 4 The TROPHY design paper summarizes several hypothetical outcomes, 5 and several commentators have criticized the design. 6, 7 In the TROPHY trial, 4 the primary aim was to determine whether active treatment reduced "the incidence of hypertension for up to 2 years after the discontinuation of treatment. " A total of 809 subjects with prehypertension, systolic blood pressure 130-139 mm Hg or diastolic blood pressure 85-89 mm Hg, were randomized to treatment with candesartan or placebo for 2 years, and they were also followed for an additional 2 years after the end of active treatment for the onset of hypertension. Blood pressure measurements were taken by an automated device at 18 fixed time points, and the outcome of hypertension was defined in several ways, including any three readings ≥140/90 mm Hg. The "carryover" hypothesis was tested directly by a comparison of the cumulative incidence of hypertension in each arm, candesartan vs. placebo, at the end of the 4-year
BAckgROunD
In randomized trials of primary prevention, there has been interest in the persistence of a beneficial effect of therapy after treatment has been stopped. We investigated the impact of measurement error in the outcome on results of the trial of preventing hypertension (TrOPHy), a trial of candesartan vs. placebo for preventing hypertension in prehypertensive subjects.
METhODS
We simulated the TrOPHy study design, assuming that candesartan reduced blood pressure by 8/6 mm Hg during treament, but had no carryover effect after treatment stopped. We simulated individual true blood pressures in the TrOPHy-eligible range of 130-140 mm Hg for systolic blood pressure and 80-90 mm Hg for diastolic blood pressure, and added individual measurement variablility. as in TrOPHy, incident hypertension was defined as any three occurrences of systolic blood pressure 140 mm Hg or diastolic blood pressure 90 mm Hg.
RESuLTS
In the absence of any carryover effect, typical incidence curves for time to hypertension were similar to those from TrOPHy. a significant difference in cumulative incidence 2 years after stopping treatment was detected in 80% simulated studies, giving a Type I error rate of 80%.
cOncLuSIOnS
The published data from TrOPHy are consistent with a lack of carryover effect of candesartan. 
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Carryover Effects After Cessation of Drug Treatment trial period. For placebo, the cumulative incidence was 63.0%, and for candesartan, it was 53.2% (relative risk 0.84, 95% confidence interval (CI) = 0.75-0.95; P = 0.007). The investigators concluded that "the effect of active treatment on delaying the onset of hypertension can extend up to 2 years after the discontinuation of treatment. " TROPHY combines and conflates two studies, one to evaluate the effect of candesartan compared with placebo on the incidence of hypertension during the first 2 years, and the second to evaluate the carryover effect of candesartan on the incidence of hypertension after stopping both candesartan and placebo during the second 2 years. Even though the outcomes were assessed in an identical fashion in the two randomized groups, the evaluation of the carryover effect was confounded because hypertension "events" detected before the start of the carryover period had started were counted in the cumulative incidence. 7 In other words, the study design of TROPHY did not take into account the random variation associated with blood pressure measurements and the effect that multiple measures of blood pressure might have on estimating the incidence of hypertension. This random variation includes both measurement error in the strict sense, and random day-to-day variability in blood pressure; we refer to these collectively as "measurement error. "
To illustrate the problem, we conducted simulations of the TROPHY design. Starting with the true average blood pressure for each prehypertensive subject at baseline, the simulations added a treatment effect for the candesartan arm (8/6 mm Hg during treatment), a linear increase in blood pressure over time, and measurement error at each time point. Following the TROPHY analysis we then used Fisher's exact test to compare the proportion with diagnosed incident hypertension in candesartan and control groups at the end of 4 year of the simulated study. To estimate the Type I error rate under each set of assumptions, we generated 10,000 simulated data sets according to the TROPHY design and counted the number of P values below 0.05. Rlanguage source code to simulate trials and draw incidence curves for a wide range of simulation scenarios is available from http://faculty.washington.edu/tlumley/inc_hyper/. Figure 1a shows the expected cumulative incidence curves for 1/0.5 mm Hg/year increase in blood pressure over time, for measurement-error standard deviations of 3/2 mm Hg, and for the absence of any carryover effect. Even though the simulation included no carryover effect, the graph closely resembles the primary outcome in TROPHY (Figure 2 in ref. 3) . Importantly, the bias seen in Figure 1a invalidates the test of "no carryover effect. " Where a valid test would reject the null hypothesis in only 5% of simulations, the Type I error in our simulations was actually 80%, and a highly significant P ≤ 0.005 was seen in 50% of simulations. In other words, when there is no carryover, the results of 16 of 20 TROPHY-like trials will be false-positive "chance" findings, a very different rate to the standard 1 of 20 trials.
These simulations show that the results of TROPHY do not provide any reliable evidence for carryover effect of candesartan. However, it is possible to construct simulation scenarios with a true carryover effect that produce results similar to those reported by TROPHY, so a carryover effect cannot be ruled out. These scenarios required a higher annual trend in blood pressure and very low levels of measurement error. In one such scenario, for instance, the average annual increase in blood pressure was 2/1 mm Hg, there was no measurement error, and the candesartan arm maintained a 2/1 mm Hg benefit in blood pressure 2 years after the end of treatment. Although data from TROPHY on the within-individual variability of systolic and diastolic blood pressure were not available, these simulations, which used a reasonable range of assumptions, suggest that blood pressure variability may be a more likely explanation for the study findings than a drug-related carryover effect.
How can future studies of hypertension incidence be designed so that a simple analysis and interpretation of the carryover hypothesis are possible? One potential approach involves taking no measurements of blood pressure during the 2-year treatment phase. In this design, measurements of blood pressure for defining the onset of hypertension would only begin after the cessation of drug treatment. If this approach were inappropriate for ethical reasons, a compromise design, in which blood pressure in prehypertensive patients was measured annually during the first 2 years, 8 reduces the Type I error rate estimated in simulations from 80 to 7%, much closer to the nominal 5% level (Figure 1b) . Defining hypertension on the basis of two or three consecutive measurements ≥140/90 would reduce the rate of false positives, but the bias would still remain substantial.
The same design requirements hold true for other continuous measures, such as lipids and glucose when threshold values are used to define onset of a clinical condition. In the DREAM trial, 3 rosiglitazone was associated with a decreased incidence of diabetes during treatment, and a planned future analysis to detect a persistent carryover benefit after the cessation of drug treatment faces the same analytic difficulties as TROPHY.
In view of the on-treatment findings for major disease outcomes in DREAM, 3 caution in making claims about posttreatment benefits solely in terms of diabetes incidence is also warranted. Compared with placebo, rosiglitazone was associated with an increased risk of cardiovascular events (relative risk = 1.37; 95% CI 0.97-1.94; P = 0.08) and with fivefold increase in the risk of heart failure (P = 0.01). In another trial, pioglitazone was also associated with an increased risk of heart failure in patients with type 2 diabetes. 9 A recent meta-analysis of the randomized trials of rosiglitazone suggests that its use is associated with a significant 43% (95% CI, 3-98%) increase in the risk of myocardial infarction (MI). 10 The sponsor's randomized trial to evaluate a composite endpoint of all cardiovascular hospitalizations and deaths provided little new information about the risk of MI. 11 The cumulative evidence, including the MI data from the RECORD study, suggests that rosiglitazone is associated with a 33% (95% CI, 2-72%) increase in the risk of MI. 12 For patients with diabetes, glycemic control with rosiglitazone is unexpectedly disconnected from the risk of MI. Whether there may be health benefits of rosiglitazone in prediabetics remains unknown and would require a large long-term trial to provide evidence.
After treatment cessation, will there also be an adverse carryover effect on the incidence of cardiovascular disease? If a new genre of clinical trials is going to evaluate drug treatments for their ability to prevent the onset of threshold-defined conditions, it will be important to conduct randomized clinical trials that also evaluate, appropriately and adequately, the health risks and benefits on important long-term clinical outcomes, including myocardial infarction, stroke, and heart failure.
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